PRLD Earnings & Financial Statements
Prelude Therapeutics Incorporated
$3.23
-$0.33(-9.27%)
37
Overall
60
Value
18
Tech
34
Quality
Market Cap
$257.77M
Volume
488.71K
52W Range
$1.16 - $6.83
Target Price
$9.00
PRLD earnings and financial statements: Prelude Therapeutics Incorporated's income statement, balance sheet and cash flow statement, annual and quarterly.
PRLD Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $12.14M | $7.00M | - | - | - |
| Operating income | -$104.57M | -$139.71M | -$132.28M | -$123.54M | -$113.73M |
| EBITDA | -$96.25M | -$123.81M | -$118.73M | -$122.22M | -$112.82M |
| Net income | -$99.50M | -$127.17M | -$121.83M | -$115.44M | -$111.69M |
| EPS (diluted) | $-1.29 | $-1.68 | $-2.02 | $-2.44 | $-2.43 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $141.31M | $175.51M | $277.67M | $220.50M | $305.10M |
| Total liabilities | $72.68M | $44.06M | $40.58M | $25.06M | $19.20M |
| Shareholders’ equity | $68.64M | $131.46M | $237.09M | $195.44M | $285.90M |
| Cash and equivalents | $35.26M | $12.47M | $25.29M | $30.61M | $31.83M |
| Long-term debt | $15.04M | $15.32M | $15.41M | - | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$56.30M | -$102.89M | -$107.06M | -$83.73M | -$83.53M |
| Capital expenditure | -$67.0K | -$764.0K | -$3.51M | -$3.02M | -$2.32M |
| Free cash flow | -$56.37M | -$103.65M | -$110.58M | -$86.75M | -$85.85M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PRLD | $3.23 | -9.3% | 488.71K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Prelude Therapeutics Incorporated Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW